Pharmaceutical News

RSS

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

GTx, Inc. today announced that the company and Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

2 Mar 2011

WARFARIN study to explore impact of genetic testing on individualized dosing

Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study was initiated in major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events.

2 Mar 2011

Study: Medication adherence alone may not benefit employees with chronic conditions

Medication adherence alone may not be enough to impact the productivity of employees with chronic conditions such as depression, diabetes, hypertension and coronary artery disease.

2 Mar 2011

Inter Press Service explores how Kenya's Anti-Counterfeit Act, possible EU-India free trade agreement could scale back access to affordable medications

Inter Press Service examines how legislation in Kenya targeting counterfeit medications and a possible EU-India Free Trade Agreement could scale back access to affordable and safe generic medications widely used in developing countries.

2 Mar 2011

Trial date set for Teva's generic COPAXONE patent infringement litigation against Momenta

Teva Pharmaceutical Industries Ltd. today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Pharmaceuticals, Inc./Mylan Inc./Natco Pharma Ltd. regarding their purported generic versions of COPAXONE® (glatiramer acetate injection).

2 Mar 2011

Four pharmaceutical companies partner to create new single-source industry

Four successful contract packaging and re-packaging companies in the pharmaceutical industry recently joined forces to create a new, single-source industry leader called Aphena Pharma Solutions.

2 Mar 2011

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS).

2 Mar 2011

Baxter announces European rMRP approval of PREFLUCEL seasonal influenza vaccine

Baxter International Inc. announced today the approval of a European repeat mutual recognition procedure (rMRP) by the Austrian Agency for Health and Food Safety for Baxter's PREFLUCEL seasonal influenza vaccine. The 13 participating European Union countries, including Germany, Spain, United Kingdom and Nordic countries, will formally implement the license on a national level to make PREFLUCEL available for the 2011-12 influenza season.

From Baxter International Inc. 2 Mar 2011

U.S. Army awards Oxygen Biotherapeutics two-year grant to study Oxycyte PFC emulsion against TBI

Oxygen Biotherapeutics, Inc. today announced it has received a $2.075 million, two-year grant from the U.S. Army to study the Company's proprietary Oxycyte PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury.

2 Mar 2011

Study: 700,000 drug-related ED visits cost nearly $1.4 billion in 2007

Over the past decade, drug-related poisonings have been on the rise in the United States. In fact, in many states drug-related poisoning deaths have now surpassed motor vehicle crash fatalities to become the leading cause of injury death. While the fatalities from this epidemic have been well reported, they are only the tip of the iceberg.

2 Mar 2011

Study: Pycnogenol- offers natural solution for patients with metabolic syndrome

The American Heart Association estimates 35 percent of adults in the U.S. suffer from metabolic syndrome, a group of risk factors characterized by obesity and the simultaneous presence of heart disease risk factors with high blood pressure, blood sugar and lipids.

2 Mar 2011

Research: Tanning bed exposure can lead to serious skin problems

Tanning bed exposure can produce more than some tanners may bargain for, especially when they self-diagnose and use the radiation to treat skin eruptions, according to research conducted by the Indiana University School of Medicine Department of Dermatology.

2 Mar 2011

EPO to grant patent for Apricus MycoVa product to treat nail fungus

Apricus Biosciences, Inc. announced today that the European Patent Office will grant a patent for the company's MycoVa product for treating onychomycosis.

2 Mar 2011

VaxInnate receives $196 million BARDA contract to develop novel flu vaccines

VaxInnate Corporation today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, worth up to $196 million to fund the development of recombinant seasonal and pandemic flu vaccines.

1 Mar 2011

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Bristol-Myers Squibb announced today that BARACLUDE(R) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B in adult patients with evidence of decompensated liver disease.

1 Mar 2011

FDA approves roflumilast to treat COPD

The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups or worsening of symptoms from severe chronic obstructive pulmonary disease.

1 Mar 2011

New drug approved for COPD by the FDA

The U.S. FDA has approved a new treatment for people with worsening symptoms of severe chronic obstructive pulmonary disease (COPD). COPD affects smokers and the elderly and leads to severe difficulty in breathing, chronic cough and excessive mucus production. An exacerbation can last up to several weeks and result in a decline in lung function and increased risk of death, and it may be associated with severe anxiety, the FDA says.

1 Mar 2011

New therapeutic strategy improves superior renal function after kidney transplantation

Researchers at Charité - Universitätsmedizin Berlin, together with 16 other transplant centers in Germany and Switzerland successfully tested a new therapeutic strategy that allows for superior renal function after kidney transplantation. The results were published online in the journal "The Lancet".

1 Mar 2011

FDA approves Forest Labs' Daliresp to treat COPD

Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

1 Mar 2011

Anti-AIDS gel shows promise

Dr. Ian McGowan, a professor of medicine at the University of Pittsburgh who is leading a second-phase study of the gel said, “These are early results, but [they] help set the stage for current and future trials of rectal microbicides and the development of a rectal-specific formulation of tenofovir gel.” Researchers have focused on the use of microbicides such as tenofovir, as a preventive treatment to be used in vaginal sex. However, scientists think unprotected anal sex is much more risky.

1 Mar 2011

Pharmaceutical News

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

WARFARIN study to explore impact of genetic testing on individualized dosing

Study: Medication adherence alone may not benefit employees with chronic conditions

Inter Press Service explores how Kenya's Anti-Counterfeit Act, possible EU-India free trade agreement could scale back access to affordable medications

Trial date set for Teva's generic COPAXONE patent infringement litigation against Momenta

Four pharmaceutical companies partner to create new single-source industry

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

Baxter announces European rMRP approval of PREFLUCEL seasonal influenza vaccine

U.S. Army awards Oxygen Biotherapeutics two-year grant to study Oxycyte PFC emulsion against TBI

Study: 700,000 drug-related ED visits cost nearly $1.4 billion in 2007

Study: Pycnogenol- offers natural solution for patients with metabolic syndrome

Research: Tanning bed exposure can lead to serious skin problems

EPO to grant patent for Apricus MycoVa product to treat nail fungus

VaxInnate receives $196 million BARDA contract to develop novel flu vaccines

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

FDA approves roflumilast to treat COPD

New drug approved for COPD by the FDA

New therapeutic strategy improves superior renal function after kidney transplantation

FDA approves Forest Labs' Daliresp to treat COPD

Anti-AIDS gel shows promise

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News